NorthWest Biotherapeutics Inc (NWBO)

[attilathehunt]

Clinical development requires the opposite. It requires freedom to adjust protocols mid-trial, to respond to immune phenotyping, to test combinations, and to refine dosing and sequencing without triggering regulatory resets. It also benefits from a fundamentally different cost structure. The Pittsburgh Innovation Core operates under a capital-light model: academic grant support tied to Dr. Kalinski’s NIH-funded programs, institutional cost-sharing through UPMC, and clinical-trial and compassionate-use manufacturing that does not require commercial-scale staffing or release overhead.

Makes perfect sense!!